UnicoCell Biomed Co., Ltd.

For over a decade, UnicoCell has been a leader in stem cell therapy research and development. Its Gold Award-winning product, ELIXCYTE®, is advancing through Phase III clinical trials for knee osteoarthritis and has completed Phase 1/2 clinical trials for chronic kidney disease, offering innovative treatments for aging-related conditions. The company follows ICH guidelines and holds a 2022 U.S. FDA Master File (MF) for its adipose-derived stem cell bank, a key material for stem cell drug development. UnicoCell has developed two patented products: Stem Cell Secretome: FDA MF-recognized and applied in treatments for degenerative eye diseases, regenerative medicine, and exosome research. UnicoVial® Ultra-Low Temperature Storage: Approved by the TFDA as a Class II medical device and FDA MF-recognized, this product is used for storing cell therapy and biological products. UnicoCell is committed to advancing stem cell technology, promoting regenerative medicine for aging-related diseases, and enhancing global quality of life.

Zouying Armed Forces General Hospital

展項一：
1.Dual-Mode Input via Speech and Text, seamlessly integrated with EMR/HIS systems to reduce nursing documentation workload and enhance clinical workflow efficiency.
2.Real-Time Multilingual Translation and Transcription, facilitating communication with new immigrants and foreign patients to build trust and improve quality of care.
3.Built-in Medical Terminology and Intelligent Autocomplete Algorithms, improving the accuracy of speech recognition and clinical documentation.
4.Emotion and Subjective Complaint Detection via NLP and Speech Analysis, supporting clinical decision-making and enabling early risk alerts.

展項二：
Utilizing AI Avatar Technology to Create Realistic Physician Models for Enhancing Patient Trust in Telemedicine
Leverage STT (Speech-to-Text), GPT, and TTS (Text-to-Speech) technologies to generate lifelike conversational experiences.
The AI digital twin can provide 24/7 consultation and health education services, unrestricted by geography and scalable for one-to-many interactions.